TS
OCUL icon

Thomas Steyer’s Ocular Therapeutix OCUL Stock Holding History

Thomas Steyer’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,000
Closed -$152K – 156
2026
Q1 		$152K Hold
18,000
– – ﹤0.01% 156
2025
Q4 		$219K Buy
+18,000
New +$219K ﹤0.01% 133
2015
Q4 		– Sell
-271,200
Closed -$3.81M – 76
2015
Q3 		$3.81M Buy
271,200
+56,200
+26% +$1.13M 0.05% 70
2015
Q2 		$4.52M Buy
+215,000
New +$5.33M 0.06% 82

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's OCUL Position: Q2 2026 in Review

Thomas Steyer sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 18,000 shares — an estimated $152K sold.

Thomas Steyer first reported a position in OCUL in Q2 2015 and held it in 4 quarters. The position peaked at $4.52M in Q2 2015. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Thomas Steyer reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 18,000 Ocular Therapeutix shares in Q2 2026, an estimated $152K.
  • Thomas Steyer first reported a position in Ocular Therapeutix in Q2 2015 and held it in 4 quarters.
  • Thomas Steyer's Ocular Therapeutix position peaked at $4.52M in Q2 2015.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.